Company Analysis Myriad Genetics, Inc.
1. Summary
Advantages
- The stock's return over the last year (61.05%) is higher than the sector average (-33.16%).
Disadvantages
- Price (23.53 $) is higher than fair price (22.42 $)
- Dividends (0%) are below the sector average (0.5496%).
- Current debt level 12.65% has increased over 5 years from 0.7949%.
- The company's current efficiency (ROE=-33.62%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Myriad Genetics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -11.1% | 1% | 1.2% |
| 90 days | -11.7% | -48.3% | 7.8% |
| 1 year | 61.1% | -33.2% | 34.2% |
MYGN vs Sector: Myriad Genetics, Inc. has outperformed the "Healthcare" sector by 94.21% over the past year.
MYGN vs Market: Myriad Genetics, Inc. has outperformed the market by 26.81% over the past year.
Stable price: MYGN is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: MYGN with weekly volatility of 1.17% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (23.53 $) is higher than the fair price (22.42 $).
Price is higher than fair: The current price (23.53 $) is 4.7% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (122.06) is higher than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (122.06) is higher than that of the market as a whole (48.12).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.33) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (2.33) is lower than that of the market as a whole (3.1).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.42) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (2.42) is lower than that of the market as a whole (10.15).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-28.36) is lower than that of the sector as a whole (-22.12).
EV/Ebitda vs Market: The company's EV/Ebitda (-28.36) is lower than that of the market as a whole (18.05).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -1164.78% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-1164.78%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).
5.4. ROE
ROE vs Sector: The company's ROE (-33.62%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-33.62%) is lower than that of the market as a whole (10.88%).
5.5. ROA
ROA vs Sector: The company's ROA (-22.97%) is lower than that of the sector as a whole (0.3359%).
ROA vs Market: The company's ROA (-22.97%) is lower than that of the market as a whole (6.5%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-0.55%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-0.55%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5496%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Selling More insider purchases by 2901.71% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 09.09.2024 | Huntington Kelly Michelle Senior VP and CFO |
Purchase | 88.64 | 44 320 | 500 |
| 03.09.2024 | Reitan Colleen F Director |
Sale | 27.95 | 1 286 040 | 46 012 |
| 21.08.2024 | Ancona Margaret SVP, Chief of Staff |
Sale | 27.82 | 320 987 | 11 538 |
| 20.01.2023 | Riggsbee Richard Bryan Chief Financial Officer |
Sale | 20.04 | 188 376 | 9 400 |
| 27.12.2022 | Riggsbee Richard Bryan Chief Financial Officer |
Sale | 15.15 | 303 000 | 20 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
